Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018... Show more
Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its best-known product remains Spikevax, its mRNA-based COVID-19 vaccine, which still accounts for nearly all revenue. The company is working to diversify through an expanded respiratory portfolio—including mFlusiva, the first mRNA-based seasonal flu vaccine, and a combined flu/COVID shot—as well as a personalized cancer vaccine program.
Investors follow MRNA closely because its pipeline represents a bet on whether mRNA technology can move beyond COVID-19 into oncology and other diseases. The company's partnership with Merck on intismeran, a personalized mRNA cancer vaccine, has become the central focus of the stock's re-rating, while a more disciplined cost structure and improving cash position have strengthened its financial foundation.
Over the past 30 days, MRNA advanced from approximately $197.00 at the October 8 close to $254.19 at the November 6 close, a gain of about 29%. The stock hit a five-year intraday high of $267.50 on November 6 before settling lower, underscoring both strong momentum and elevated volatility.
The move is even more pronounced over the full quarter. In early August, MRNA traded near $54; by early November it had reached roughly $254, a gain of about 370%. Most of that advance came in a single session on August 19, when the stock surged after positive Phase 3 data for its cancer vaccine, followed by months of wide trading ranges between roughly $180 and $250.
The sharpest catalyst was Moderna's third-quarter earnings report on November 6. The company returned to profitability for the first time in two years, reporting revenue of $1.31 billion, net income of $162 million, and diluted EPS of $0.38, far ahead of analyst expectations for a loss. Stronger-than-expected international COVID-19 vaccine sales, driven by long-term government partnerships, fueled the beat.
Management also lifted its full-year 2026 revenue growth guidance to 15%–25% and raised its projected year-end cash balance to $8.1–$8.3 billion, partly reflecting reduced R&D spending and roughly $2.6 billion in convertible note proceeds. These figures signaled improving financial discipline and extended the post-earnings rally.
Earlier in the period, sentiment swung around intismeran. After full Phase 3 melanoma data was released at a European medical conference in October, shares initially dropped roughly 17% in a single session amid a partial data leak and profit-taking, before recovering as analysts and investors digested the complete results.
The quarterly trend was defined by the August 19 announcement that intismeran, combined with Merck's Keytruda, met its primary endpoint in a Phase 3 melanoma trial. The readout drove a historic single-day surge in MRNA shares and established oncology as the market's central investment thesis for the stock.
Regulatory and pipeline milestones reinforced the move. The U.S. FDA approved mFlusiva in August—the first mRNA-based seasonal flu vaccine—and the company secured additional approvals for its flu and combination vaccines in Canada and Europe. A patent settlement with GSK in October removed a legal overhang, while the company's cost-cutting program and convertible financing strengthened its balance sheet. These developments transformed MRNA from a COVID-dependent story into a broader mRNA platform narrative.
Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots drawn from a much larger universe of hundreds of automated strategies trading thousands of tickers. Only the top-performing and most relevant bots appear in this section, giving traders a focused view of strategies that are currently standing out. The bots differ in trading style, holding timeframe, and performance metrics, so users can compare approaches rather than rely on a single signal. For those seeking a data-driven complement to their own analysis, exploring the page offers a practical way to see which AI strategies are gaining momentum.
Near term, Moderna's analyst day on November 12 is a key event where management is expected to detail commercialization plans and pipeline timelines. Investors are also watching for the regulatory submission of intismeran, which Moderna and Merck are preparing, with a potential U.S. approval decision in 2027.
Additional readouts matter, including renal cell carcinoma data expected late in 2026 or early 2027 and updates on the paused norovirus program. The limited U.S. launch of mFlusiva and the seasonality of COVID-19 vaccine demand will shape near-term revenue, while the elevated share price leaves the stock sensitive to valuation concerns and any setback in the cancer program. No forward-looking statement here should be taken as investment advice.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The 10-day RSI Indicator for MRNA moved out of overbought territory on November 05, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 instances where the indicator moved out of the overbought zone. In 26 of the 28 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MRNA as a result. In 74 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
The Moving Average Convergence Divergence Histogram (MACD) for MRNA turned negative on November 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 33 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.
MRNA moved below its 50-day moving average on November 18, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRNA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
MRNA broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +11.41% 3-day Advance, the price is estimated to grow further. Considering data from situations where MRNA advanced for three days, in 217 of 277 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
The Aroon Indicator entered an Uptrend today. In 108 of 130 cases where MRNA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 83%.
The Tickeron Valuation Rating of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.010) is normal, around the industry mean (3.596). P/E Ratio (-31.853) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.040) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (25.907) is also within normal values, averaging (443.347).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. MRNA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MRNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of transformative medicines for patients
Industry Biotechnology